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Comments on pre-fibrotic myelofibrosis and how should it be
managed
We read with great interest the recent paper by Curto-Garcia
et al (2018) regarding the problems and pitfalls concerning
the diagnosis of pre-fibrotic myelofibrosis (pre-PMF) and
appreciate that the authors recognize this subtype of myelo-
proliferative neoplasm (MPN). While the article addresses a
very timely and important topic with high impact for clinical
practice and management of patients, we would like to high-
light and discuss a few critical issues. The controversies
underlying the debates concerning pre-PMF, which had been
included in the 2001 World Health Organization (WHO)
myeloid classification scheme as “chronic idiopathic myelofi-
brosis pre-fibrotic stage” (Jaffe et al, 2001), derive from mul-
tiple reasons that will be briefly discussed below.
It is of note that, although bone marrow (BM) morphol-
ogy remains the cornerstone of diagnosis, the WHO clas-
sification envisions a strictly integrated approach, i.e. a
multi-disciplinary process including clinical and molecular
genetic findings. In this context, baseline clinical data and
treatment-na€ıve representative BM biopsy specimens are
mandatory (Swerdlow et al, 2017) to facilitate the evaluation
of BM features according to standardized parameters (Thiele
et al, 2011). As has been pointed out, diagnostic reliability
compared with other haematological disorders may be prob-
lematic concerning a more limited intra-and inter-observer
reproducibility. Referring to the case reports and abstracts of
pre-PMF, accurate fibre grading (WHO 0–1/3) is essential (e.g.
a simple ≥ grade 1 is not adequate). The main clinical and
haematological variables and, very importantly, outcome, have
been shown to correlate with fibrosis grading (Guglielmelli
et al, 2017). The problems and pitfalls that can be encountered
when including the role of BM morphology in the crucial dif-
ferentiation between pre-PMF and essential thrombocythaemia
(ET), have been highlighted previously (Thiele et al, 2011; Gis-
slinger et al, 2016). Therefore, we strongly recommend to
reclassify the initial BM biopsies derived from older cohorts
according to 2016 WHO criteria, particularly in patients who
were classified as ET based on previous diagnostic criteria.
Rumi et al (2017) reported that, of the 358 “old” ET cases, 268
(75%) were reclassified as ET, 25 (7%) as unclassifiable and 65
(18%) as pre-PMF. The latter patients had a higher risk of
overt myelofibrosis (97% vs. 0% at 10 years) compared to
those reclassified as WHO-defined ET.
The clinical presentation of pre-PMF patients appropriately
diagnosed according to the revised WHO definition (Swerdlow
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et al, 2017) reveals a high degree of consistency between clini-
cal data, BM morphology and presence of the following find-
ings :borderline anaemia (25%), leucocytosis (51%), elevated
lactate dehydrogenase (79%) and palpable splenomegaly
(45)%; more than 90% of pre-PMF cases initially show one or
more of the above features that represent minor diagnostic cri-
teria compared to about 48% of ET patients (Jeryczynski et al,
2017). Constitutional symptoms were reported in only 20%,
significantly lower than in overt PMF (34%; Guglielmelli et al,
2017). It should be emphasised that, except for establishing
clonal evolution, molecular data or cytogenetic findings are
not useful to differentiate pre-PMF from ET.
As has been emphasised, prognosis is significantly different
between pre-PMF and ET. When regarding data from several
large studies on 1383 adult patients with pre-PMF vs. 2125
patients with WHO-defined ET, the overall median, cumula-
tive or relative and sex-/age-adjusted relative survival revealed
significant differences, with ET patients having almost double
the overall median survival of pre-PMF patients (Thiele et al,
2011; Guglielmelli et al, 2017) or a 10/15-year cumulative
incidence of death (Barbui et al, 2011). By using the five inde-
pendent predictors of inferior survival (age >65 years, haemo-
globin <100 g/l, leucocyte count >25 9 109/l, circulating blasts
>1%, constitutional symptoms), Guglielmelli et al (2017) cal-
culated that 48% of pre-PMF patients were in the low-risk
group, 40% in the intermediate 1+ plus 2 group and only 12%
were included in the high risk group, which was significantly
different from overt PMF.
Regarding therapy, given that the majority of patients lie
within the International Prognostic Scoring System lower
prognostic group, observation alone can be recommended.
Patients with intermediate risk may require a symptom-dri-
ven treatment for anaemia, splenomegaly or constitutional
symptoms. On the other hand, high risk patients should be
treated as overt PMF, as has been recently reviewed by
Finazzi et al (2018). A pragmatic approach to address the
risk of bleeding and thrombosis includes: no treatment or
low-dose aspirin in asymptomatic patients; aspirin or oral
anticoagulation if previous arterial or venous thrombosis,
and hydroxycarbamide as first-line cytoreduction in case of
thrombocytosis or leucocytosis.
Additionally, we have to address the differences in published
cohorts of pre-PMF patients that may be caused by the method
of recruitment. The first bias is the retrospective selection from
archived material and reclassification. The second is that selec-
tion may be focused either on ET or PMF cases derived from
archive material and, rarely, initially-presenting patients. Con-
sequently, cohorts with a more “ET-like” phenotype (high pla-
telet counts, low percentage of patients with WHO fibrosis
grade 1 versus groups with a more “PMF-like” phenotype
(lower platelet counts, high percentage of WHO fibrosis grade
1 may be encountered. Concerning transformation to acute
myeloid leukaemia, Barbui et al (2011) reported an incidence
of 58% at 10 years, including 24% patients with WHO fibrosis
grade 1, in contrasting with Guglielmelli et al (2017), who
reported an incidence of 12%, including 72% patients with
fibrosis grade 1. In contrast, Jeryczynski et al (2017) investi-
gated the whole spectrum of routinely presenting 170 pre-PMF
patients, including 146% of cases with platelet counts
<450 9 109/l and grade 1 fibrosis in 35% of cases. Pre-PMF
patients that present with initial reticulin fibrosis may con-
tribute to a more aggressive course of disease. The cumulative
incidences of progression to overt PMF at 10 years were calcu-
lated to reach 315% (Jeryczynski et al, 2017). These data are
substantially higher compared to previously published results
(123% and 97% at 10 years), respectively, mostly recruited
from ET-archived cases (Barbui et al, 2011; Rumi et al, 2017).
In conclusion, the present situation calls for multicentre
prospective studies on pre-PMF with a centralized pathology
review of the BM biopsy specimens by experts, to improve
diagnostic reliability and provide prospective analysis of phe-
notype presentation, clinical course and outcome.
Acknowledgements
TB and JT authors wrote the paper that was approved by the
other contributors.
Conflict of interest
The authors declare no conflict of interest.
Tiziano Barbui1
Juergen Thiele2
Heinz Gisslinger3
Attilio Orazi4
Alessandro M. Vannucchi5
Umberto Gianelli6
Christine Beham-Schmid7
Ayalew Tefferi8
1FROM Research Foundation, Papa Giovanni XXIII Hospital,
Bergamo, Italy, 2Institute of Pathology, University of Cologne, Cologne,
Germany, 3Department of Internal Medicine I, Division of Haematol-
ogy and Haemostaseology, Medical University of Vienna, Vienna, Aus-
tria, 4Department of Pathology and Laboratory Medicine, Weill Cornell
Medical College, New York, NY, USA, 5Department of Experimental
and Clinical Medicine, Centre of Research and Innovation of Myelopro-
liferative Neoplasms, Azienda Ospedaliera Universitaria Careggi,
University of Florence, Florence, 6Division of Pathology, Department of
Pathophysiology and Transplantation, University of Milan, and IRCCS
Ca’ Granda—Maggiore Policlinico Hospital Foundation, Milan, Italy,
7Institute of Pathology, Medical University of Graz, Graz, Austria and
8Mayo Clinic, Rochester, MN, USA.
E-mail: tbarbui@asst-pg23.it
Keywords: pre-fibrotic myelofibrosis, essential thrombocythaemia,
clinical data, bone marrow morphology, prognosis
First published online 7 March 2019
doi: 10.1111/bjh.15840
Correspondence
ª 2019 British Society for Haematology and John Wiley & Sons Ltd 359
British Journal of Haematology, 2019, 186, 327–384
References
Barbui, T., Thiele, J., Passamonti, F., Rumi, E.,
Boveri, E., Ruggeri, M., Rodeghiero, F.,
d’Amore, E.S., Randi, M.L., Bertozzi, I., Marino,
F., Vannucchi, A.M., Antonioli, E., Carrai, V.,
Gisslinger, H., Buxhofer-Ausch, V., M€ullauer, L.,
Carobbio, A., Gianatti, A., Gangat, N., Hanson,
C.A. & Tefferi, A. (2011) Survival and disease
progression in essential thrombocythemia are
significantly influenced by accurate morphologic
diagnosis: an international study. Journal of
Clinical Oncology, 29, 3179–3184.
Curto-Garcia, N., Ianotto, J.-C. & Harrison, C.N.
(2018) What is pre-fibrotic myelofibrosis and
how should it be managed in 2018? British Jour-
nal of Haematology, 183, 23–34.
Finazzi, G., Vannucchi, A.M. & Barbui, T. (2018)
Prefibrotic myelofibrosis: treatment algorithm.
Blood Cancer Journal, 8, 104.
Gisslinger, H., Jeryczynski, G., Gisslinger, B.,
W€olfler, A., Burgstaller, S., Buxhofer-Ausch, V.,
Schalling, M., Krauth, M.-T., Schiefer, A.-I.,
Kornauth, C., Simonitsch-Klupp, I., Beham-
Schmid, C., M€ullauer, L. & Thiele, J. (2016)
Clinical impact of bone marrow morphology for
the diagnosis of essential thrombocythemia:
comparison between the BCSH and the WHO
criteria. Leukemia, 30, 1126–1132.
Guglielmelli, P., Pacilli, A., Rotunno, G., Rumi, E.,
Rosti, V., Delaini, F., Maffioli, M., Fanelli, T.,
Pancrazzi, A., Pietra, D., Salmoiraghi, S., Man-
narelli, C., Franci, A., Paoli, C., Rambaldi, A.,
Passamonti, F., Barosi, G., Barbui, T., Cazzola,
M. & Vannucchi, A.M.; AGIMM Group. (2017)
Presentation and outcome of patients with 2016
WHO diagnosis of prefibrotic and overt primary
myelofibrosis. Blood, 129, 3227–3236.
Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman,
J.W.E. (eds.) (2001) World Health Organization
Classification of Tumours. Pathology and Genetics
of Tumours of Haematopoietic and Lymphoid Tis-
sues, 1st edn. International Agency for Research
on Cancer Press, Lyon, France.
Jeryczynski, G., Thiele, J., Gisslinger, B., W€olfler, A.,
Schalling, M., Gleiß, A., Burgstaller, S., Buxhofer-
Ausch, V., Sliwa, T., Schl€ogl, E., Geissler, K.,
Krauth, M.-T., Nader, A., Vesely, M., Simonitsch-
Klupp, I., M€ullauer, L., Beham-Schmid, C. & Gis-
slinger, H. (2017) Pre-fibrotic/early primary
myelofibrosis vs. WHO-defined essential throm-
bocythemia: the impact of minor clinical diagnos-
tic criteria on the outcome of the disease.
American Journal of Hematology, 92, 885–891.
Rumi, E., Boveri, E., Bellini, M., Pietra, D., Fer-
retti, V.V., Sant’Antonio, E., Cavalloni, C., Case-
tti, I.C., Roncoroni, E., Ciboddo, M., Benvenuti,
P., Landini, B., Fugazza, E., Troletti, D., Astori,
C. & Cazzola, M. (2017) Clinical course and
outcome of essential thrombocythemia and pre-
fibrotic myelofibrosis according to the revised
WHO 2016 diagnostic criteria. Oncotarget, 8,
101735–101744.
Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe,
E.S., Pileri, S.A., Stein, H. & Thiele, J. (eds.)
(2017) WHO Classification of Tumours of Hae-
matopoietic and Lymphoid Tissues, 4th edn.
International Agency for Research on Cancer
Press, Lyon, France.
Thiele, J., Kvasnicka, H.M., M€ullauer, L., Bux-
hofer-Ausch, V., Gisslinger, B. & Gisslinger, H.
(2011) Essential thrombocythemia versus early
primary myelofibrosis: a multicenter study to
validate the WHO classification. Blood, 117,
5710–5718.
Index of Pain Experience in Sickle Cell Anaemia (IPESCA):
development from daily pain diaries and initial findings from
use with children and adults with sickle cell anaemia
Pain burden assessments are essential to evaluate the effective-
ness of interventions in sickle cell anaemia (SCA) treatment
trials. Number of days in pain or number of hospital admis-
sions are commonly utilised but these measures overlook addi-
tional important clinical information captured in complex
pain diaries that are challenging to quantify and summarise.
We created a simple, intuitive composite index (Index of Pain
Experience in Sickle Cell Anaemia [IPESCA]), which reflects
frequency as well as location, intensity and type of pain.
The sample included 61 children and adults screened for
the Prevention of Morbidity in Sickle Cell Anaemia (POMS)
phase-II randomised controlled trial (Howard et al, 2018).
At screening visit, patients completed a paper pain diary for
14 consecutive days, which included shading locations of
pain on a body map, circling words to describe their pain
and choosing a 0–10 numerical rating of pain intensity. The
body map diagram (von Baeyer et al, 2011) was divided into
18 specific areas, and the widespread pain index (WSPi)
(Zempsky et al, 2017) comprised the total number of body
locations in pain over the two-week period. Eight of 21
descriptor words were classified as ‘neuropathic’ (e.g. aching,
stabbing, numb, shooting, pricking, burning, penetrating,
radiating) (Wilkie et al, 2010). IPESCA is a novel summary
measure, consisting of four components: WSPi, maximum
persistence of pain, defined as the total number of days in
pain at any one location, total number of neuropathic words
chosen, and mean of daily average pain intensity. The com-
ponents were equally weighted using this equation:
f xð Þ ¼ ðmax new½  min½newÞðx min½originalÞ
max½original min½original þmin½new
and scaled to range 0–025 to create a summed index (range
0–1).
Patients also completed the validated Sickle Cell Pain Bur-
den Inventory-Youth (SCPBI-Y) questionnaire (Zempsky
et al, 2013), which assesses the past month’s impact of pain
on physical, social and emotional aspects of daily function.
The SCPBI-Y was completed at the screening visit and at
randomisation visit 30 days later, together representing the
previous 2 months of pain burden.
Analyses were performed using R version 3.3.2 (www.r-pro
ject.org). Demographics were compared using the t-test for
continuous variables, the chi-squared test or Fisher’s exact test
for categorical variables. IPESCA was tested for skewness and
kurtosis using the R ‘moments’ package (Komsta &
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